Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
Mattias Ekstedt, Hannes Hagström, Patrik Nasr et al. · Hepatology · 2014
UNLABELLED: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the Western world, strongly associated with insulin resistance and the metabolic syndrome. Nonalcoholic steatohepatitis, i.e., fatty liver accompanied by necroinflammatory changes, is mostly defined by the NAFLD activity score (NAS). The aim of the current study was to determine disease-specific mortality in NAFLD, and evaluate the NAS and fibrosis stage as prognostic markers for overall and disease-specific mortality. In a cohort study, data from 229 well-characterized patients with biopsy-proven NAFLD were collected. Mean follow-up was 26.4 (±5.6, range 6-33) years. A reference population was obtained from the National Registry of Population, and information on time and cause of death were obtained from the Registry of Causes of Death. NAFLD patients had an increased mortality compared with the reference population (hazard ratio [HR] 1.29, confidence interval [CI] 1.04-1.59, P = 0.020), with increased risk of cardiovascular disease (HR 1.55, CI 1.11-2.15, P = 0.01), hepatocellular carcinoma (HR 6.55, CI 2.14-20.03, P = 0.001), infectious disease (HR 2.71, CI 1.02-7.26, P = 0.046), and cirrhosis (HR 3.2, CI 1.05-9.81, P = 0.041). Overall mortality was not increased in patients with NAS 5-8 and fibrosis stage 0-2 (HR 1.41, CI 0.97-2.06, P = 0.07), whereas patients with fibrosis stage 3-4, irrespective of NAS, had increased mortality (HR 3.3, CI 2.27-4.76, P < 0.001). CONCLUSION: NAFLD patients have increased risk of death, with a high risk of death from cardiovascular disease and liver-related disease. The NAS was not able to predict overall mortality, whereas fibrosis stage predicted both overall and disease-specific mortality.
Cited by 2,278 works. doi:10.1002/hep.27368
Authors
- Mattias Ekstedt
- Hannes Hagström
- Patrik Nasr
- Mats G. Fredrikson
- Per I Stal
- Stergios Kechagias
- Rolf W. Hultcrantz
References
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆
- The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
- Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡
- Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults
- Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
- Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population
- Clinical and Histologic Spectrum of Nonalcoholic Fatty Liver Disease Associated With Normal Alt Values
- Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
- Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States